A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD

PHASE3CompletedINTERVENTIONAL

Enrollment

1,767

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

May 31, 2016

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Flutiform

DRUG

Formoterol

Trial Locations (15)

Sofia

Hamburg

Budapest

Riga

Vilnius

Skopje

Trzemeszno Lubuskie

Bacau

Moscow

Prešov

Cape Town

Gyeonggido

Barcelona

Kyiv

London

All Listed Sponsors

lead

Mundipharma Research Limited

INDUSTRY

NCT01946620 - A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD | Biotech Hunter | Biotech Hunter